Idenix Pharmaceuticals Inc. (Nasdaq: IDIX) reported continued progress of its nucleotide prodrug development program to treat hepatitis C infection. Shares of the biopharmaceutical climbed 64 cents to close at $5.81.
Progress Continues For Idenix
April 07, 2014 at 19:16 PM EDT
